
Cell and Gene Therapy Company
Production capacity financed against the equipment, not against earnings the company had not reached yet.
A therapeutics company building its own production capacity
A cell and gene therapy company in Southern California, moving from development into controlled production in its own facility.
Strong backing, real assets, and no EBITDA to show a credit committee
The company had investors, programs and a clear need for cleanroom and production equipment. What it did not have was the trading history a conventional credit process is built to assess. Banks looked for earnings that a company at this stage does not generate by design. The alternative was funding capital equipment out of the equity raised to fund science, which is the most expensive money in the building.
Underwritten on the equipment and the backing behind it
Alliance Funding Group structured the facility around the assets and the strength of the company's funding position rather than around historical earnings. Financing the laboratory and production equipment separately from the equity meant the raise stayed committed to programs rather than being consumed by fit-out.
In-house capacity, with the raise left doing what it was raised for
The company brought production capacity in-house on its own timeline, holding processes and intellectual property inside the business rather than at a contract manufacturer. The equity raised for research remained available for research.
Get Started
Ready to become our next success story?
Let's discuss how we can help your business achieve results like these.











